Immutep Limited: Continuing To Make The Case For Eftilagimod

2025-01-28 16:37:29 ET

Summary

• Immutep Limited remains a “Buy” due to promising pipeline updates and strong financials, despite inherent high-risk/high-reward dynamics.
• Key trials for eftilagimod show encouraging results, particularly in non-small cell lung cancer and soft tissue sarcoma, enhancing the drug's potential.
• Financially, IMMP has a cash runway at least to 2026, supporting ongoing and future clinical trials without immediate funding concerns.
• Recent clinical data suggest meaningful advancements in LAG-3 therapeutics, reinforcing the investment thesis and highlighting IMMP's undervalued status.

Topline Summary and Update

Read the full article on Seeking Alpha

For further details see: